The p2 / p3 blended OSA trial will cost significantly less than that, closer to $20m. It’s not a function of multiplying the number of sites by $2.5m, although I understand why you made that calculation.
The 2025 estimate is a genuine budget running all trials (refer page 26 of presentation) based on cash in bank plus R&D rebates where applicable.
Importantly the company can complete all this work regardless of market conditions in the next couple of years. That’s leadership.
IHL Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
